Trials / Completed
CompletedNCT00911898
A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
A Phase 1 and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Merrimack Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label Phase 1 trial of MM-111.
Detailed description
Phase 1: Patients with any solid tumor type may be enrolled to evaluate the safety and tolerability of MM-111.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MM-111 | For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
- First posted
- 2009-06-03
- Last updated
- 2015-01-13
- Results posted
- 2014-09-15
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00911898. Inclusion in this directory is not an endorsement.